GSK GlaxoSmithKline
- 41.110
- +0.200+0.49%
- 41.660
- +0.550+1.34%
GlaxoSmithKline News
Global Pulmonary Drugs Market Is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Grifols, Regeneron
New York, USA, April 25, 2024 (GLOBE NEWSWIRE) -- Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca,
GlaxoSmithKline sues Pfizer and BioNTech over mRNA vaccine technology
GLONGHUI, April 25 | GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing on the company's patents relating to RNA (mRNA) technology. GlaxoSmithKline claims Pfizer's and BioNTech's ComirNaty vaccine infringes on the company's patent for an mRNA vaccine innovation developed “more than a decade before the COVID-19 pandemic broke out.” A Pfizer spokesperson said in a statement that they are confident of our intellectual property position in Comirnaty and intend to make a “strong defense” against GlaxoSmithKline's claim.
CureVac Begins Early Stage Portion of Investigational Vaccine Trial
CureVac (CVAC) said Wednesday it initiated the early stage portion of a broader study into an investigational flu vaccine developed with GSK (GSK). The phase 1 trial is part of a combined phase 1/2 st
CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus
CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influen
CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of Health
CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of Health
The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer
The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primar
Sanofi Reportedly Lining up Banks for Consumer Products Spinoff
As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNA
Unusual Options Activity: CSX, FNV and Others Attract Market Bets, CSX V/OI Ratio Reaches 152.2
EST Apr 22nd Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend
GlaxoSmithKline rose about 3% in the UK market
Gronghui, April 22 | Sanofi will pay $100 million to settle the Zantac cancer lawsuit. GlaxoSmithKline (London stock price, UK) increased its increase to 2.7%.
Sanofi will pay $100 million to settle the Zantac cancer lawsuit. GlaxoSmithKline (London stock price, UK) increased its increase to 2.7%.
Sanofi will pay $100 million to settle the Zantac cancer lawsuit. GlaxoSmithKline (London stock price, UK) increased its increase to 2.7%.
Sanofi To Pay $100M To Settle Zantac Cancer Lawsuits
Sanofi To Pay $100M To Settle Zantac Cancer Lawsuits
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Drug shortages in the UK have more than doubled between 2020 and 2023, a recent study by the Nuffield Trust reveals. Brexit is cited as a significant factor exacerbating the country's struggle to mana
The protective effect reached 82% after 10 years! Long-term follow-up results of GSK (GSK.US) shingles vaccine announced
The Zhitong Finance App learned that GSK (GSK.US) recently announced its recombinant herpes zoster vaccine Shingrix (RZV), which obtained positive data in the long-term follow-up phase 3 clinical trial ZOSTER-049. The trial tracked participants for about 11 years after receiving Shingrix. The final data showed that RZV was effective in protecting adults over 50 against shingles for more than ten years. Shingles is caused by reactivation of varicella-zoster virus (VZV), which is also the causative agent of chickenpox. Most adults already have this virus in their bodies, and can
GSK Shingles Vaccine Shown 82% Effective 11 Years After Vaccination
Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)
GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital Gonorrhea
Gepotidacin achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatmentEAGLE-1 is the third positive pivotal trial for gepotidacin, a potential first-in-cla
GSK Says New Long-Term Data Show Shingrix Continues To Provide Protection Against Shingles In Adults Aged 50 And Over For More Than A Decade
GSK Says New Long-Term Data Show Shingrix Continues To Provide Protection Against Shingles In Adults Aged 50 And Over For More Than A Decade
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial
British drugmaker GSK (GSK.L) on Wednesday said a phase 3 trial of its gepotidacin drug for treating uncomplicated urogenital gonorrhea in adolescents and adults met its primary endpoint. The oral ant
Analysis
Price Target
No Data
